Inhalation of stable dust extract prevents allergen induced airway inflammation and hyperresponsiveness

M Peters, M Kauth, J Schwarze, C Körner-Rettberg, J Riedler, D Nowak, C Braun-Fahrlander, E von Mutius, A Bufe, O Holst, the ALEX Study Group

Background: Recent epidemiological studies have shown that growing up on a traditional farm provides protection from the development of allergic disorders such as hay fever and allergic asthma. We present experimental evidence that substances providing protection from the development of allergic diseases can be extracted from dust collected in stables of animal farms.

Methods: Stable dust was collected from 30 randomly selected farms located in rural regions of the Alps (Austria, Germany and Switzerland). The dust was homogenised with glass beads and extracted with physiological sodium chloride solution. This extract was used to modulate immune response in a well established mouse model of allergic asthma.

Results: Treatment of mice by inhalation of stable dust extract during sensitisation to ovalbumin inhibited the development of airway hyperresponsiveness and airway eosinophilia upon challenge, as well as the production of interleukin 5 by splenocytes and of antigen specific IgG1 and IgE. Dust extract also suppressed the generation of human dendritic cells in vitro. The biological activity of the dust extract was not exclusively mediated by lipopolysaccharide.

Conclusions: Stable dust from animal farms contains strong immune modulating substances. These substances can interfere with the development of both cellular and humoral immunity against allergens, thus suppressing allergen sensitisation, airway inflammation, and airway hyperresponsiveness in a murine model of allergic asthma.

Background: Recent epidemiological studies have shown that growing up on a traditional farm provides protection from the development of allergic disorders such as hay fever and allergic asthma. We present experimental evidence that substances providing protection from the development of allergic diseases can be extracted from dust collected in stables of animal farms.

Methods: Stable dust was collected from 30 randomly selected farms located in rural regions of the Alps (Austria, Germany and Switzerland). The dust was homogenised with glass beads and extracted with physiological sodium chloride solution. This extract was used to modulate immune response in a well established mouse model of allergic asthma.

Results: Treatment of mice by inhalation of stable dust extract during sensitisation to ovalbumin inhibited the development of airway hyperresponsiveness and airway eosinophilia upon challenge, as well as the production of interleukin 5 by splenocytes and of antigen specific IgG1 and IgE. Dust extract also suppressed the generation of human dendritic cells in vitro. The biological activity of the dust extract was not exclusively mediated by lipopolysaccharide.

Conclusions: Stable dust from animal farms contains strong immune modulating substances. These substances can interfere with the development of both cellular and humoral immunity against allergens, thus suppressing allergen sensitisation, airway inflammation, and airway hyperresponsiveness in a murine model of allergic asthma.

Methods:

Collection of stable dust

A total of 30 farming households were selected, all located in rural regions of the Alps where the previous field studies were also conducted. Sediment dust from cattle and goat stables was collected by scraping off all surfaces at a height of

Abbreviations: AHR, airway hyperresponsiveness; BAL, bronchoalveolar lavage; IFN-γ, interferon γ; IL, interleukin; LPS, lipopolysaccharide; PBS, phosphate buffered saline
Mice were sensitised by intraperitoneal injection of 20 μg dust. All experimental procedures were approved by the animal ethics committee at Bezirksregierung in Arnsberg. Female BALB/c mice (Charles River, Sulzfeld, Germany) aged 7–8 weeks were used and acclimated to the animal facility for 14 days before the experiments. The animals had access to food and water ad libitum. All experimental procedures were approved by the animal ethics committee at Bezirksregierung Arnsberg.

**Extraction of stable dust**

For homogenisation of the dust, 15 g of glass beads (0.4–0.6 mm in diameter) were added to 10 g dust, double distilled water was added to give a final volume of 70 ml, and the sample was homogenised in a Braun MSK homogeniser (B Braun, Melsungen, Germany). Five samples (1 = 50 g of dust) were combined and extracted with 0.9% aqueous sodium chloride (NaCl) solution (total volume 5 litres) for 6 hours at 22 °C with continuous stirring. After centrifugation the dust extract was dialysed against water and then lyophilised.

**Sensitisation and airway challenge**

Mice were sensitised by intraperitoneal injection of 20 μg ovalbumin (OVA gradeV; Sigma, St Louis, MO, USA) emulsified in 2.2 mg aluminium hydroxide (ImjectAlum; Pierce, Rockford, IL, USA) in a total volume of 200 μl on days 1 and 14. On days 28 and 38 mice were challenged via the airways with 1% OVA aerosol for 20 minutes (fig 1) using a PARI-Boy aerosol generator. Controls were injected with aluminium hydroxide alone and challenged with PBS aerosol (non-sensitised).

**Treatment of animals with stable dust extract**

Mice were treated with stable dust extract during the sensitisation phase (fig 1). Extract was administered as aerosol generated from a 10 mg/ml solution. For treatment, the mice were placed in a plexiglass chamber (volume 11 litres) which was connected to a PARI-Boy Turbo jet stream aerosol generator (PARI, Starnberg, Germany) and allowed to inhale the aerosol for 20 minutes. Mice were treated 14 times beginning on the day of the first OVA injection and the last treatment 6 days before the second OVA aerosol challenge (fig 1). Control groups were sensitised as described above and treated 14 times with either phosphate buffered saline (PBS) or 0.8 μg/ml E coli LPS during the sensitization phase. The LPS concentration was chosen to match the concentration in the dust extract detected by Limulus amebocyte lysate assay. The E coli LPS used in the study was purified at Forschungszentrum Borstel.

Inhilation of dust extract 20 min

**Figure 1** Design of in vivo experiments. OVA i.p. denotes systemic immunisation with ovalbumin adsorbed in aluminium hydroxide. OVA aerosol indicates challenges with 1% ovalbumin aerosol via the airways. AR, airway responsiveness. Analysis indicates harvest of bronchoalveolar lavage fluid cells, serum, and splenocytes for analysis.

0.05–0.15 m (racks, tables, tools) with a metal spatula. From each farm 100–200 g dust was collected and passed through a conventional kitchen sieve. All dust samples were then combined.

In stimulation assays with human mononuclear cells it is highly biological active, and induces maximal tumour necrosis factor (TNF)-α release at a concentration of 2 ng/ml and maximal IL-10 release at 0.4 ng/ml.

**Airway responsiveness**

24 hours after the last aerosol challenge airway hyperresponsiveness (AHR) to methacholine aerosol (0, 6, 12, 25 and 50 mg/ml, Sigma) was evaluated in conscious unrestrained mice using whole body plethysmography (Buxco Electronics) by measuring the enhanced pause (Penh). Previous studies have shown that the AHR to methacholine reaches its maximum 24 hours after OVA challenge. Furthermore, it has been shown that, in this experimental setting, AHR assessed by Penh correlates closely with increases in airway resistance in ventilated animals.

**In vitro cytokine production of mouse splenocytes**

Spleens were harvested 3 days after the second aerosol challenge. Single cell suspensions were prepared by mechanical disruption and erythrocytes were lysed. Spleen cells were then cultured in a concentration of 5×10⁶/ml in complete tissue culture medium (CTCM) (RPMI 1640 with 10% fetal calf serum (FCS), 2 mM l-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, all from Biochrom, Berlin, Germany). To stimulate specific cytokine production, OVA was added to a final concentration of 50 μg/ml. After 48 hours of culture, supernatants were taken and stored at −80°C until analysis. Levels of IL-5 and IL-10 were assessed using optEIA kits (BD Biosciences, Heidelberg, Germany) according to the manufacturer’s instructions.

**Bronchoalveolar lavage (BAL)**

Three days after OVA challenge the lungs were lavaged via a tracheal tube with 2×1 ml PBS and leucocytes in the lavage fluid were counted. After centrifugation, BAL fluid was frozen for further analysis. Cytospin slides of BAL cells were stained with a fast staining procedure (HAEME-Schnellfärbung, Labor+Technik Eberhard Lehmann, Berlin, Germany) according to the manufacturer’s instructions. The percentages of eosinophils, lymphocytes, and macrophages in BAL fluid samples were determined by light microscopy. At least 300 cells per sample were differentiated by a blinded investigator.

**Measurement of OVA specific IgG₁, IgG₂a and IgE in serum and BAL fluid**

Blood was collected by tail vein puncture 2 days after the second aerosol challenge. BAL fluid was collected as described above. Levels of OVA specific IgG₁, IgG₂a and IgE in serum or BAL fluid were determined by ELISA. Briefly, sample wells of a Nunc maxisorb ELISA plate (Nunc, Wiesbaden, Germany) were coated with 5 μg/ml OVA overnight and then blocked with 1% bovine serum albumin. After incubation with diluted samples, bound OVA specific antibodies were detected with isotype specific antibodies, rat anti-mouse IgG₂a (clone R19-15) and rat anti-mouse IgG₁ (clone X56), both conjugated to alkaline phosphatase or biotinylated rat anti-mouse IgE (clone R35-72) (all from BD Biosciences). The latter antibody was detected by horseradish peroxidase conjugated extravidin (Sigma). In control experiments isotype specific rat anti-mouse IgE antibody does not cross react with IgG₁ or IgG₂a isotype. Serum levels of OVA specific IgG₁ and IgE were related to combined standard sera generated in our laboratory and expressed as arbitrary units per ml. Levels of OVA specific IgG₂a in 1/10 diluted serum were expressed as optical density measured at a wavelength of 405 nm (OD₄₀₅).
Generation of human dendritic cells in vitro

Human monocyte derived dendritic cells were generated essentially as described elsewhere. Briefly, mononuclear cells were isolated from the peripheral blood of healthy volunteers by Ficoll-Paque density gradient centrifugation. Monocytes were purified by centrifugal elutriation or adherence to plastic for 2 hours at 37°C each yielding similar results. Purified monocytes were cultured at 37°C in 5% CO₂ for 7 days at 1×10⁶/ml in CTCM supplemented with 500 U/ml recombinant human GM-CSF, 500 U/ml recombinant human IL-4 (both from PeproTech, London, UK) and with or without 25 μg/ml dust extract or 2 ng/ml LPS from *E coli* as a matched control to the LPS content of dust extract. Every other day 50% of the medium was replaced by fresh prewarmed medium containing the same supplements. To induce maturation, 250 ng/ml LPS were added on day 6 and cells were incubated for another 24 hours.

Flow cytometric analysis

Flow cytometric analysis of monocyte and DC specific surface antigens was performed on a FACSCalibur flow cytometer (BD Biosciences). The following fluorescein isothiocyanate (FITC) or phycoerythrin (PE) conjugated mouse anti-human monoclonal antibodies were used for direct labeling of the cells: antiCD1a-PE (clone BL6), antiCD14-FITC (RMO52), both from Beckman-Coulter, Krefeld, Germany. Isotype matched monoclonal antibodies of irrelevant specificity were used as controls.

Allogenic mixed lymphocyte reaction

The T cell stimulatory capacity of monocyte derived dendritic cells generated in the presence or absence of dust extract was determined by measuring induction of interferon-γ (IFN-γ) in an allogenic mixed lymphocyte reaction. 1×10⁶ monocyte derived dendritic cells were incubated with 1×10⁶ allogenic lymphocytes in a 96-well flat bottom cell culture plate (Nunc, Wiesbaden, Germany) for 96 hours in CTCM. Concentrations of IFN-γ were assessed in cell free supernatants by ELISA (IFN-γ OptEIA Set, BD Biosciences).

![Figure 2](image)

**Figure 2** Airway responsiveness following exposure to stable dust extract during sensitisation. Airway responsiveness to methacholine was measured 24 hours after the second challenge with ovalbumin (OVA) in mice treated by inhalation of dust extract (*n* = 16) or sham treated with phosphate buffered saline (PBS; *n* = 16) during sensitisation. Another control group was treated during sensitisation by inhalation of lipopolysaccharide (LPS) as a matched control to the LPS content of dust extract (*n* = 8). Median Penh values from groups of mice were related to the methacholine concentrations used for provocation. Whiskers represent the 25–75th percentile of median values. **p<0.001** dust extract treated mice v PBS treated mice.

Statistical analysis

Statistical analysis was performed to test whether treatment with dust extract leads to a significant reduction in several parameters associated with allergic disease. For this purpose, data from the mouse model were analysed by the two tailed Mann-Whitney test. In vitro studies with human leucocytes were analysed by the two tailed Wilcoxon matched pairs test. Graph Pad Prism Software (Version 3.03) was used for analysis. Values of *p*<0.05 were considered statistically significant. All results are presented as median with 25–75th percentile in parentheses.

RESULTS

Effect of treatment with stable dust extract on AHR

Following sensitisation and challenge with OVA, the mice developed marked AHR compared with non-sensitised controls (fig. 2). To examine the influence of stable dust extract on allergen induced AHR, mice were exposed to an aerosol of dust extract during sensitisation and first challenge. Mice treated with dust extract were nearly unresponsive to methacholine provocation as non-sensitised mice. In contrast, treatment of mice with a solution containing 0.8 μg/ml *E coli* LPS as a matched control to the LPS content of dust extract did not reduce AHR. Treatment of non-sensitised mice with dust extract did not induce changes in airway reactivity (data not shown).

Suppression of airway eosinophilia following treatment with stable dust extract

In addition to AHR, allergic asthma is characterised by airway inflammation with predominant infiltrates of eosinophils. As shown in fig. 3, the BAL fluid of non-sensitised mice contained only moderate numbers of macrophages, no lymphocytes, and no eosinophils. After sensitisation and challenge with OVA, eosinophils (primarily) and also lymphocytes and macrophages were recruited to the airways to give BAL fluid levels of 9.6×10⁵ (7.6–11.5×10⁵) eosinophils and 1×10⁵ (0.8–1.1×10⁵) lymphocytes. Treatment of
mice with LPS did not have any significant effect on cell recruitment to the airways induced by sensitisation and challenge. In contrast, treatment with stable dust extract led to a significant suppression of eosinophil and lymphocyte recruitment to the airways, with BAL fluid levels of $0.4 \times 10^5$ (0.2–0.7 $\times 10^5$) eosinophils and $0.3 \times 10^5$ (0.2–0.7 $\times 10^5$) lymphocytes.

### Influence of treatment with dust extract on production of Th2 cytokines

Airway eosinophilia is dependent on the secretion of Th2 type cytokines, especially IL-5, from Th2 lymphocytes as a consequence of allergic sensitisation. Accordingly, sensitisation caused induction of Th2 cytokines with increased in vitro production of IL-5 and IL-10 in splenocyte cultures restimulated with OVA (table 1). However, in vitro production of IL-5 by splenocytes from sensitised and dust treated mice was reduced by about 63% compared with sensitised mice treated with PBS. Treatment with LPS, however, did not result in a significant reduction in sensitisation induced IL-5 concentrations in vitro. Production of IL-10 did not seem to be affected by inhalation of dust extract.

### Table 1 Effect of inhaled dust extract on IL-5 and IL-10 production of murine splenocytes

<table>
<thead>
<tr>
<th>Treatment</th>
<th>IL-5 (pg/ml)</th>
<th>IL-10 (pg/ml)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS</td>
<td>834 (625.5–1002)</td>
<td>1499 (1164–1782)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>LPS</td>
<td>1080 (806.5–1420)</td>
<td>1816 (1482–2030)</td>
<td>0.4398</td>
</tr>
<tr>
<td>Dust extract</td>
<td>309 (248–402.3)</td>
<td>1275 (842.8–1742)</td>
<td>0.1275</td>
</tr>
<tr>
<td>Non-sensitised</td>
<td>5.2 (0–16.5)</td>
<td>91.5 (78–124)</td>
<td>0.1456</td>
</tr>
</tbody>
</table>

IL, interleukin; PBS, phosphate buffered saline; LPS, lipopolysaccharide.

In vitro production of IL-5 and IL-10 was measured by ELISA after restimulation of splenocytes with OVA for 2 days; n=8 per group. Results are presented as median with 25–75th percentile in parentheses. Dust extract treated mice were compared with PBS treated mice by the two tailed Mann-Whitney test.

### Influence of stable dust extract on development of humoral immune responses to allergens

Serum levels of OVA specific IgG1 and IgE antibodies increased substantially after sensitisation (table 2). Following treatment with dust extract during sensitisation, the production of both OVA specific IgG1 and IgE was reduced compared with mice sham treated with PBS during sensitisation. Inhalation of LPS during sensitisation did not have any significant effect on the production of either antibody isotype. Interestingly, OVA specific IgG2a antibodies, which are associated with Th1 responses and which were only marginally but significantly increased in the serum after sensitisation and challenge, did not increase in concentration following treatment with dust extract.

### Table 2 Effect of inhaled dust extract on serum antibody production in mice

<table>
<thead>
<tr>
<th>Treatment</th>
<th>IgE ($\times 10^5$ U/ml)</th>
<th>IgG1 ($\times 10^5$ U/ml)</th>
<th>IgG2a (OD450)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS</td>
<td>2.7 (1.7–5.6)</td>
<td>11.1 (8.1–19.6)</td>
<td>0.15 (0.13–0.27)</td>
</tr>
<tr>
<td>LPS</td>
<td>2.2 (1.3–5.6)</td>
<td>13.3 (8.4–26.7)</td>
<td>0.14 (0.13–0.3)</td>
</tr>
<tr>
<td>Dust extract</td>
<td>1.3 (0.9–2.0), p=0.017</td>
<td>5.5 (2.0–8.1), p=0.001</td>
<td>0.17 (0.13–0.2)</td>
</tr>
<tr>
<td>Non-sensitised</td>
<td>0</td>
<td>0</td>
<td>0.09</td>
</tr>
</tbody>
</table>

PBS, phosphate buffered saline; LPS, lipopolysaccharide.

Serum levels of OVA specific IgE, IgG1, IgG2a were measured by ELISA and expressed as arbitrary units; n=8 per group. The results are presented as median with the 25–75th percentile in parentheses. Dust extract treated mice were compared with PBS treated mice by the two tailed Mann-Whitney test.
To determine local antibody responses in the airways during allergic inflammation, OVA specific IgE was also measured in BAL fluid. B. IgE titres in sensitised and sham treated mice were significantly higher than in non-sensitised mice which did not have any detectable OVA specific antibodies in BAL fluid. Inhalation of dust extract significantly reduced IgE titres in BAL fluid (fig 4) while treatment with LPS had no significant effect.

**Reduced T cell stimulatory capacity of human dendritic cells generated in the presence of stable dust extract**

Allergen induced airway inflammation and AHR are thought to depend on T cell responses. T cells in turn require activation by specialised antigen presenting dendritic cells. To determine whether dendritic cell differentiation can be inhibited by substances present in the dust extract, we tested the influence of the extract on in vitro generation of monocyte derived dendritic cells.

Monocytes isolated from human blood were cultured in the presence of GM-CSF and IL-4 for 7 days resulting in dendritic cell differentiation as demonstrated by expression of CD1a and downregulation of CD14 (fig 5). The presence of 2 ng/ml E coli LPS (concentration matched to LPS concentration in dust extract) during culture did not seem to have an influence on dendritic cell differentiation with respect to upregulation of CD1a and downregulation of CD14. In contrast, the presence of dust extract inhibited the GM-CSF and IL-4 (G/I) induced differentiation of monocytes, reducing upregulation of CD1a while partially maintaining CD14 expression. These incompletely differentiated cells had a reduced T cell stimulatory capacity in allogenic mixed lymphocyte reactions as measured by IFN-γ release. In the presence of cells differentiated with dust extract, IFN-γ production was significantly reduced by 37.1% compared with IFN-γ concentrations in mixed lymphocyte reactions with monocyte derived dendritic cells generated in the absence of dust extract (G/I = 7.0 ng/ml (5.5–32.9); G/I+ dust extract = 4.4 ng/ml (1.2–15.1); n = 6; p = 0.03). Monocyte derived dendritic cells from matched LPS control cultures did not significantly change IFN-γ production in mixed lymphocyte reactions (G/I+LPS = 6.6 ng/ml (5.4–19.1), not significant (p = 0.16) versus G/I).

**DISCUSSION**

In this study we present evidence that dust collected from stables of traditional farms contains biologically active factors which, after interaction with physiological sodium chloride solution and administration by inhalation, can protect mice from allergic sensitisation, eosinophilic airway inflammation, and resulting AHR. This is the first experimental approach to confirm the epidemiological observation that exposure to the stable environment of traditional farms reduces the risk of allergic diseases.1–4

The method used in our study to extract substances from stable dust is likely to be comparable to the natural situation in the bronchial mucosa where salt containing mucosal fluid probably extracts similar substances from inhaled stable dust particles. The effect of dust extract inhalation was particularly strong on AHR and airway inflammation, while the protective activity of inhaled dust extract on systemic sensitisation was less pronounced. Mean antibody titres (IgG1, and IgE) in the serum of mice treated with dust extract were only slightly reduced. This indicates that inhaled dust extract mainly acts locally in the airways, inhibiting effects of airway allergen challenges and, to a lesser extent, the systemic responses to intraperitoneal sensitisation with OVA and aluminium hydroxide. This interpretation is further supported by the observation that, in contrast to serum levels, local concentrations of OVA specific IgE in BAL fluid were markedly reduced after dust extract inhalation. These findings indicate that the anti-allergic effects of dust extract would be even more pronounced in a model of sensitisation exclusively via the airways. Such a model may reflect allergen sensitisation in infants more closely than intraperitoneal hyperimmunisation used in this study.

Several authors have observed similar reductions in airway symptoms after treatment with solutions of microbes or microbial compounds. Broide et al showed that bacterial CpG oligodeoxynucleotides led to suppression of allergen induced asthma in mice, and Hopfenspirger et al found that treatment with mycobacterial antigens could attenuate allergen induced airway eosinophilia and deterioration of lung function even in mice with established allergic airway inflammation.5 6 17–19

Furthermore, there is a body of information regarding the effects of LPS in mouse models of asthma which shows that systemic treatment with LPS in relatively high doses results in at least partial reduction of allergic symptoms.20 In all of these experiments LPS seemed to induce a shift towards Th1 responses. This is in contrast to our findings of slight enhancement of Th2 responses following LPS treatment and a lack of Th1 response after inhalation of stable dust extract. This difference may be due to the comparatively low concentration of LPS in stable dust extract and the matched LPS concentration used in our control experiments. It has been shown previously that low concentrations of LPS are not only unable to inhibit allergic sensitisation and Th2 responses, but that they can even enhance these.21 Although the endotoxin concentration in dust extract is too low to inhibit sensitisation of mice, we cannot exclude the possibility that it acts synergistically with other immune modulatory substances of farm dust as Roy et al22 have shown for IL-10 and IL-12 release of human peripheral blood mononuclear cells after stimulation with barn dust DNA in vitro.

Considering the lack of a Th1 shift, it is likely that the immune modulation induced by stable dust extract was based on the induction of immunological tolerance or suppression. This hypothesis is supported by our results showing that human monocyte derived dendritic cells generated in the presence of dust extract showed a much weaker T cell stimulatory capacity than those generated without dust extract. This lack of stimulatory capacity was associated with persistent CD14 and reduced CD1a expression, indicating incomplete differentiation from monocytes into dendritic cells in the presence of dust extract. The stable dust extract may therefore exert an influence on allergic immune responses by modulating differentiation and function of antigen presenting cells (APC). It is tempting to speculate that modulation of APC differentiation by components of stable dust may lead to unresponsiveness of allergen specific T cells. Although we do not present direct evidence for this hypothesis, our data indicate downregulation of the T cell response rather than activation.

Finally, the finding that stable dust extract used in our study contained immune modulatory substances which were able to inhibit the development of allergic sensitisation, eosinophilic airway inflammation, and changes in lung function could lead to the new prophylactic treatments for the prevention of allergic diseases. In particular, the observation that inhalation of stable dust extract resulted in suppression or unresponsiveness rather than induction of Th1 responses against the allergen makes stable dust derived compounds interesting candidates for therapeutic approaches in humans, since the lack of Th1 induction may reduce the risk of undesirable side effects such as autoimmunity.23

In summary, we have established an experimental schedule which will allow the identification of relevant
biologically active compounds in the inhaled stable dust extract. Using this experimental schedule, our study shows that it is possible to extract highly active substances from stable dust which can suppress sensitisation in a mouse model of allergic asthma. The priority now is to define the active factors in stable dust and to establish their precise mode of action.

ACKNOWLEDGEMENTS

The authors are indebted to their collaborators in the ALEX Study Group (David Carr and Rudolf Schierl, Munich, Germany; Waltraud Eder, Tucson, USA; Udo Herz and Harald Renz, Marburg, Germany; Roger P. Lauener, Zurich, Switzerland; Marco Waser, Basel, Switzerland) and thank Britta Steeger, Petra Fritz, Petra Behrens, and Erika Flacke for excellent technical assistance.

Authors’ affiliations

M Peters, M Kauth, A Bufe, Department of Experimental Pneumology, Ruhr-University Bochum, Bochum, Germany
O Holst, Division of Structural Biochemistry, Forschungszentrum Borstel, Leibniz-Center for Medicine and Biosciences, Borstel, Germany
J Schwarze, Department of Respiratory Medicine, National Heart and Lung Institute, Imperial College, London, UK
J Schwarze, C Körner-Rettberg, Klinik für Kinder- und Jugendmedizin, St Josef-Hospital, Bochum, Germany
J Riedler, Kinderspital Schwarzhach, Schwarzhach, Austria
D Nowak, Institute of Occupational and Environmental Medicine, University of Munich, Munich, Germany
C Braun-Fahrländer, Institute of Social and Preventive Medicine, Basel, Switzerland
E von Mutius, Dr von Hauner Children’s Hospital, Munich, Germany

This study was supported by grants from the Deutsche Forschungsgemeinschaft (DFG: BU-762/5-1, HO-1259/4-1).

Competing interests: none.

MP and MK contributed equally to the manuscript.

REFERENCES


Inhalation of stable dust extract prevents allergen induced airway inflammation and hyperresponsiveness

M Peters, M Kauth, J Schwarze, C Körner-Rettberg, J Riedler, D Nowak, C Braun-Fahrländer, E von Mutius, A Buße and O Holst

*Thorax* 2006 61: 134-139 originally published online October 21, 2005
doi: 10.1136/thx.2005.049403

Updated information and services can be found at:
http://thorax.bmj.com/content/61/2/134

**References**

This article cites 21 articles, 6 of which you can access for free at:
http://thorax.bmj.com/content/61/2/134#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Asthma (1782)
- Inflammation (1020)
- Ear, nose and throat/otolaryngology (218)
- Epidemiologic studies (1829)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/